Denosumab in the treatment of osteoporosis associated with chronic kidney disease

Osteoporosis is a substantial health concern worldwide, particularly among individuals with advanced chronic kidney disease (CKD). In this population, bone fragility is a prevalent complication attributable to disruptions in mineral and hormonal equilibria, leading to a non-vertebral-fracture risk that is 4 to 6 times higher than that of matched control individuals. 1 Evenepoel P Cunningham J Ferrari S et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrol Dial Transplant. 2021; 36: 42-59 Crossref PubMed Google Scholar